+

WO2018153900A1 - Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2 - Google Patents

Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2 Download PDF

Info

Publication number
WO2018153900A1
WO2018153900A1 PCT/EP2018/054246 EP2018054246W WO2018153900A1 WO 2018153900 A1 WO2018153900 A1 WO 2018153900A1 EP 2018054246 W EP2018054246 W EP 2018054246W WO 2018153900 A1 WO2018153900 A1 WO 2018153900A1
Authority
WO
WIPO (PCT)
Prior art keywords
sulfanyl
methyl
thiazol
chlorophenyl
phenoxy
Prior art date
Application number
PCT/EP2018/054246
Other languages
German (de)
English (en)
Inventor
Barbara ALBRECHT-KÜPPER
Stephan Vettel
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of WO2018153900A1 publication Critical patent/WO2018153900A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • the present invention relates to selective partial adenosine A1 receptor agonists in combination with SGLT-2 (sodium dependent glucose transporter) inhibitors and their use for the treatment and / or prophylaxis of cardiovascular and renal diseases.
  • Adenosine a purine nucleoside
  • Adenosine is present in all cells and is released from a variety of physiological and pathophysiological stimuli.
  • Adenosine is produced intracellularly in the degradation of adenosine 5'-monophosphate (AMP) and S-adenosyl homocysteine as an intermediate, but can be released from the cell and then functions as a hormone-like substance or neurotransmitter by binding to specific receptors.
  • AMP adenosine 5'-monophosphate
  • S-adenosyl homocysteine as an intermediate, but can be released from the cell and then functions as a hormone-like substance or neurotransmitter by binding to specific receptors.
  • adenosine increases the perfusion of the coronary arteries and has a cardioprotective effect. It also affects blood pressure, heart rate, neurotransmitter release and lymphocyte differentiation. In the kidney, it has a renopro- tective effect. In adipocytes, adenosine is able to inhibit lipolysis and thus reduce the concentration of free fatty acids and triglycerides in the blood.
  • adenosine aim to increase the supply of oxygen in the affected organs, to make the energy production more efficient or to reduce the metabolism of these organs in order to achieve an adaptation of the organ metabolism to the organ perfusion under ischemic or hypoxic conditions.
  • adenosine receptor-selective ligands are those substances which bind selectively to one or more subtypes of the adenosine receptors and either mimic the action of adenosine (adenosine agonists) or block its action (adenosine antagonists).
  • adenosine receptors are mediated intracellularly by the messenger cAMP.
  • A1 receptors inhibition of adenylate cyclase causes a decrease in intracellular cAMP content.
  • the main effects are the activation of adenosine A1 receptors: bradycardia, negative inotropy, protection of the heart from ischemia ("preconditioning") and improvement of energy production and utilization Receptors affect diuresis and protect kidney function in kidney disease and ischaemia.
  • A1 receptors in the heart can be exploited, inter alia, by activation of these A1 receptors by specific A1 agonists for treatment and organ protection in acute myocardial infarction, acute coronary syndrome, heart failure, bypass surgery, cardiac catheterization and organ transplantation ,
  • full A1 receptor agonists have the disadvantage that it can also lead to the induction of unwanted physiological effects, such as bradycardia to AV block and central CNS effects. This can be circumvented by partial A1 receptor agonists.
  • Partial A1 receptor agonists have a lower efficiency at the A1 receptor than full receptors and result in a selective activation of physiological effects with a high receptor reserve.
  • the protective effect of partial A1 receptor agonists in the kidney can be used for the treatment and organ protection of chronic kidney disease.
  • A1 receptors In adipocytes, activation of A1 receptors causes inhibition of lipolysis.
  • Lowering lipids in turn, can reduce insulin resistance and improve symptoms in patients with metabolic syndrome and diabetics.
  • the aforementioned selectivity on the A1 receptor can be determined by the effect of the substances on cell lines expressing the A1 receptor after stable transfection with the corresponding cDNA (see J. Biol. Chem. 1992, 267, 10764-10770).
  • the effect of the substances on such cell lines can be detected by biochemical measurement of the intracellular messenger cAMP (see Naunyn Schmiedebergs Arch. Pharmacol., 1998, 357, 1-9).
  • the degree of partiality can be evaluated by a GTP shift assay (see J. Med. Chem. 1995, 38, 4000-4006).
  • the "adenosine receptor-specific" ligands known from the prior art are predominantly derivatives based on natural adenosine (see Bioorg.Med.Chem 1998, 6, 619-641) . These known adenosine ligands However, they usually have the disadvantage that after oral administration they are only very weak or very short-acting or have undesirable side effects on, for example, the central nervous system (CNS) (see Curr Topics Med. Chem. 2003, 3, 369-385; Exp. Opin. Invest. Drugs 2008, 17, 1901- 1910). Therefore, they are mainly used only for experimental purposes. In the treatment of cardiovascular and renal diseases, A1 R agonists have so far played no role and there are no drugs in the clinic that address this mechanism.
  • CNS central nervous system
  • Prodrugs are derivatives of an active substance which undergo a single or multistage biotransformation of enzymatic and / or chemical nature in vivo before the actual active substance is released.
  • a prodrug residue is usually used to improve the property profile of the underlying drug (J. Med. Chem. 2004, 47, 2393-2404, H. Bundgaard (Ed.), Design of Prodrugs: Bioreversible Derivatives for various functional groups and chemical entities, Elsevier Science Publishers BV, 1985, Curr Drug Metab., 2003, 4, 461-485, Curr. Eye Res., 2004, 26, 151-163).
  • the design of the prodrug residue as well as the desired release mechanism must be very precisely matched to the individual active ingredient, the indication, the site of action and the route of administration.
  • a large number of drugs are administered as prodrugs which have improved bioavailability over the underlying drug, for example, by improving physicochemical profile, especially solubility, active or passive absorption properties, or tissue specific distribution.
  • SGLT-2 sodium dependent glucose transporter
  • SGLT-2 sodium-glucose linked transporter 2
  • SGLT-2 sodium-glucose linked transporter 2
  • SGLT-2 inhibitors mimic this effect and inhibit the renal sodium-dependent glucose transporter type 2 (SGLT-2) in the renal tubules. This promotes the concentration-dependent urinary excretion of glucose. This leads to both a lowering of the blood sugar concentration and to a calorie loss, without, however, causing a hypoglycemia. This mechanism of lowering blood sugar is independent of insulin action and secretion as well as of insulin resistance or lack of insulin production by the beta cells of the pancreas. In clinical studies, SGLT-2 inhibitors have been shown to significantly reduce cardiovascular mortality in patients with heart failure (see New Engl. J. Med. 2015, 373, 21 17-28).
  • the mechanism behind the cardiovascular benefits of SGLT-2 inhibitors is multifunctional and involves changes in arterial stiffness, cardiac function, cardiac oxygen demand, and cardiac-renal effects, such as reduction albuminuria, lowering uric acid and effects on hyperglycemia, body weight and blood pressure.
  • the object of the present invention is therefore to provide combinations of pharmaceutical agents for the treatment of cardiovascular diseases, in particular also cardiac insufficiency, which reduce the mortality and / or morbidity in patients and show an additional benefit to the pure lowering of the heart rate, without the Mean arterial blood pressure or heart rate significantly further influence.
  • the solution of the above object and the subject of the present invention are the following combinations of selective partial adenosine A1 receptor agonists with a SGLT-2 inhibitor.
  • the combination of selective partial adenosine A1 receptor agonists with a SGLT-2 inhibitor results in further cardioprotection without additional haemodynamic effects on blood pressure and heart rate.
  • the combination is therefore suitable for the treatment and / or prophylaxis of diseases, preferably of cardiovascular diseases, in particular for the treatment and / or prophylaxis of cardiac insufficiency with preserved ejection fraction or cardiac insufficiency with reduced ejection fraction and renal diseases.
  • Suitable SGLT-2 inhibitors include dapagliflozin, empagliflozin, canagliflozin, ipragliflozin and toulafloxin.
  • Dapagliflozin is the compound (1S) -1,5-anhydro-1- [4-chloro-3- (4-ethoxybenzyl) phenyl] -D-glucitol of the formula (A)
  • Canagliflozin is the compound (1S) -1,5-anhydro-1- (3 - ⁇ [5- (4-fluorophenyl) -2-thienyl] methyl ⁇ -4-methylphenyl) -D-glucitol of the formula (C)
  • Ipragliflozin is the compound (1S) -1,5-anhydro-1- [3- (1-benzothiophen-2-ylmethyl) -4-fluorophenyl] -D-glucitol of the formula (D)
  • Tofogliflozin is the compound (1 S ! 3'R ! 4'S ! 5'S ! 6'R) -6- (4-ethylbenzyl) -6 '- (hydroxymethyl) -3' ! 4 ' ! 5 ', 6'-tetrahydro-3H-spiro [2-benzofuran-1, 2'-pyran] -3', 4 ', 5'-triol of the formula (E)
  • Selective partial adenosine A1 receptor agonists are already known: in WO 01/25210, WO 02/070484, WO 02/070485, WO 2002/070520, WO 03/053441, WO 2008/028590, WO 2008/064789, WO 2009 / 100827, WO 2009/015776, WO 2009/015812, WO 2009/1 12155 and WO 2009/143992 disclose various substituted 3,5-dicyano-6-aminopyridines as adenosine receptor ligands for the treatment of cardiovascular diseases.
  • WO 2006/027142 describes substituted phenylaminothiazoles
  • WO 2008/064788 describes cyclically substituted 3,5-dicyanopyridines
  • WO 2009/080197 discloses substituted azabicyclic adenosine receptor ligands
  • WO 2009/01581 1, WO 2009/015812, WO 2010/072314 and WO 2010/072315 describe amino acid ester prodrugs of 3,5-dicyano-6-aminopyridines.
  • WO2010 / 086101 discloses other adenosine receptor ligands for the treatment of cardiovascular diseases.
  • WO 03/053441 and WO 07/073855 (A1) selective A1 receptor agonists of the type 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine in combination with aminoglycosides are used to protect renal cells from antibiotic-induced Renal cell damage described.
  • WO2009 / 01581 1 discloses prodrug derivatives of 2-amino-6 - ( ⁇ [2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl ⁇ thio) -4- [4- (2-hydroxyethoxy ) Phenyl] pyridine-3,5-dicarbonitrile and, inter alia, its use in acute renal failure and nephropathy.
  • WO 10/086101 describes various alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs and, in addition to the primary use in cardiovascular diseases, inter alia, also their use in kidney diseases.
  • Preferred selective adenosine A1 receptor agonists in the context of the present invention combinations are:
  • the combinations according to the invention allow an effective treatment of cardiovascular diseases, in particular also cardiac insufficiency, whereby the mortality and / or morbidity in patients is further reduced without significantly influencing the mean arterial blood pressure or heart rate.
  • cardiovascular diseases in particular also cardiac insufficiency
  • the above-described disadvantages of the forms of therapy known in the prior art such as the still high demand for a further reduction in morbidity and / or mortality without additional hemodynamic effect, could be further addressed.
  • Another object of the present invention is the use of selective partial adenosine A1 receptor agonists in combination with a SGLT-2 inhibitor for the treatment of cardiovascular diseases, e.g. Cardiac insufficiency with preserved ejection fraction or cardiac insufficiency with reduced ejection fraction and renal diseases as well as other disease manifestations (e.g., end-organ damage affecting the heart and kidney).
  • cardiovascular diseases e.g. Cardiac insufficiency with preserved ejection fraction or cardiac insufficiency with reduced ejection fraction and renal diseases as well as other disease manifestations (e.g., end-organ damage affecting the heart and kidney).
  • Another object of the present invention are selective partial adenosine A1 receptor agonists in combination with a SGLT-2 inhibitor and their use for the treatment of cardiovascular diseases such as heart failure with received ejection fraction or heart failure with reduced ejection fraction and renal diseases as well as other manifestations of the disease (eg end-organ damage affecting the heart and kidney).
  • cardiovascular diseases such as heart failure with received ejection fraction or heart failure with reduced ejection fraction and renal diseases as well as other manifestations of the disease (eg end-organ damage affecting the heart and kidney).
  • Preferred subject matter of the invention are selective partial adenosine A1 receptor agonists in combination with an SGLT-2 inhibitor, such as by way of example and preferably dapagliflozin, empagliflozin, canagliflozin, ipragliflozin and tofogliflozin.
  • an SGLT-2 inhibitor such as by way of example and preferably dapagliflozin, empagliflozin, canagliflozin, ipragliflozin and tofogliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (4) and dapagliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (4) and empagliflozin.
  • Preferred subject of the present invention are combinations containing the compound of formula (4) and canagliflozin.
  • Preferred subject of the present invention are combinations containing the compound of formula (4) and Ipragliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (4) and tofogliflozin.
  • Preferred subject of the present invention are combinations containing the compound of formula (12) and dapagliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (12) and empagliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (12) and canagliflozin.
  • Preferred subject of the present invention are combinations containing the compound of formula (12) and Ipragliflozin.
  • Preferred subject matter of the present invention are combinations containing the compound of formula (12) and tofogliflozin.
  • the components to be combined may be present as salts.
  • Salts which are preferred in the context of the present invention are physiologically acceptable salts of the compounds to be combined. Also included are salts which are not suitable for pharmaceutical applications, but which can be used, for example, for the isolation or purification of the compounds to be combined.
  • Another object of the present invention are combinations according to the invention for the treatment and / or prophylaxis of diseases, wherein the compound of formula (4) once daily and the SGLT-2 inhibitor once daily.
  • Another object of the present invention are combinations according to the invention for the treatment and / or prophylaxis of diseases, wherein 5-40 mg of the compound of formula (4) and 10-100g of the SGLT-2 inhibitor are administered.
  • Another object of the present invention are combinations according to the invention for the treatment and / or prophylaxis of diseases, wherein the compound of formula (12) once daily and the SGLT-2 inhibitor once daily.
  • Another object of the present invention are combinations according to the invention for the treatment and / or prophylaxis of diseases, wherein 5-40 mg of the compound of formula (12) and 10-100 mg of the SGLT-2 inhibitor are administered.
  • Another object of the present invention are the combinations according to the invention for the treatment and / or prophylaxis of diseases.
  • the compounds according to the invention are suitable alone or in combination with one or more other active substances for the prevention and / or treatment of various diseases, for example diseases of the cardiovascular system (cardiovascular diseases), for cardioprotection after damage to the heart as well as metabolic and renal diseases.
  • diseases of the cardiovascular system cardiovascular diseases
  • cardioprotection after damage to the heart as well as metabolic and renal diseases.
  • Another object of the present invention is a medicament containing at least one combination according to the invention in combination with an inert, non-toxic, pharmaceutically suitable excipient.
  • Another object of the present invention is a medicament containing at least one combination according to the invention in combination with one or more further active ingredients selected from the group consisting of ACE inhibitors, renin inhibitors, beta-blockers, acetylsalicylic acid, diuretics, calcium antagonists, statins, Digitalis (digoxin) derivatives, calcium sensitizers, nitrates and antithrombotics.
  • Another object of the present invention is a medicament containing at least one combination of the invention for the treatment of various diseases, such as diseases of the cardiovascular system (cardiovascular diseases), for cardioprotection after damage to the heart as well as metabolic and renal diseases.
  • diseases of the cardiovascular system cardiovascular diseases
  • cardioprotection after damage to the heart as well as metabolic and renal diseases.
  • Another object of the present invention is methods for the treatment and / or prophylaxis of various diseases, such as diseases of the cardiovascular system (cardiovascular diseases), for cardioprotection after damage to the Her- zens and metabolic and renal diseases in humans and animals using at least one combination according to the invention.
  • diseases of the cardiovascular system cardiovascular diseases
  • cardioprotection after damage to the Her- zens and metabolic and renal diseases in humans and animals using at least one combination according to the invention.
  • the invention also relates to the combination of separate pharmaceutical compositions in kit form.
  • kit form This is a kit comprising two separate entities: a pharmaceutical composition of a selective partial adenosine A1 receptor agonist and a pharmaceutical SGLT-2 inhibitor composition.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (4) and a pharmaceutical composition comprising dapagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (4) and a pharmaceutical composition comprising empagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (4) and a pharmaceutical composition comprising canagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (4) and a pharmaceutical composition comprising ipragliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (4) and a pharmaceutical composition comprising tofogliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (12) and a pharmaceutical composition comprising dapagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (12) and a pharmaceutical composition comprising empagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (12) and a pharmaceutical composition comprising canagliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (12) and a pharmaceutical composition comprising ipragliflozin.
  • the invention also relates to a preferred kit form comprising two units: A pharmaceutical composition comprising the compound of formula (12) and a pharmaceutical composition comprising tofogliflozin.
  • the kit form is particularly advantageous when the separate components must be administered in different dosage forms or administered at different dose intervals.
  • cardiovascular diseases such as hypertension, resistant hypertension, acute and chronic heart failure, heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF) coronary heart disease and unstable angina pectoris, peripheral and cardiac vascular diseases, arrhythmias, arrhythmias, atrial and ventricular arrhythmias and conduction disorders such as atrio-ventricular blockade grade l-lll (AB block l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular fibrillation ternary ventricular tachyarrhythmia, torsade de pointes tachycardia, atrial and ventricular extrasystoles, atrioventricular extrasystoles, sick sinus syndrome, syncope, AV node reentrant tachycardia, Wolff-Park
  • cardiac insufficiency includes both acute and chronic manifestations of heart failure, as well as more specific or related Forms of the disease such as acute congestive heart failure, right heart failure, left ventricular insufficiency, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects, heart failure heart valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, nalklappenstenose aortic regurgitation, tricuspid stenosis, tricuspid insufficiency, Pulmo, Pulmonalklappeninsuffizienz , combined heart valve defects, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, diastolic heart failure and systolic
  • the combinations according to the invention may also be used for the treatment and / or prophylaxis of arteriosclerosis, lipid metabolism disorders, hypolipoproteinemias, dyslipidaemias, hypertriglyceridemias, hyperlipidemias, hypercholesterolemias, abetelipoproteinaemia, sitosterolemia, xanthomatosis, Tangier disease, obesity (obesity) and obesity combined hyperlipidaemias and the metabolic syndrome, as well as type 1 diabetes
  • the combinations according to the invention can be used for the treatment and / or prophylaxis of primary and secondary Raynaud's phenomenon, microcirculatory disorders, cladidatio, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangren, CREST syndrome, erythematosis , Onychomycosis, rheumatic diseases and to promote wound healing.
  • the combinations according to the invention are also suitable for the treatment of muscular dystrophy, such as Becker-Kiener muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
  • the combinations according to the invention are suitable for the treatment and / or prophylaxis of urological diseases such as benign prostatic syndrome (BPS), benign prostatic hyperplasia (BPH), benign prostate enlargement (BPE), bladder emptying disorder (BOO), lower urinary tract syndromes (LUTS) Feiines urological syndrome (FUS)), diseases of the urogenital system including neurogenic overactive bladder (OAB) and (IC), incontinence (Ul) such as mixed, urge, stress, or overflow incontinence (MUI, UUI, SUI , OUI), pelvic pain, benign and malignant diseases of the organs of the male and female urogenital system.
  • BPS benign prostatic syndrome
  • BPH benign prostatic hyperplasia
  • BPE benign prostate enlargement
  • BOO bladder emptying disorder
  • LUTS lower urinary tract syndromes
  • Feiines urological syndrome Feiines urological syndrome
  • diseases of the urogenital system including neurogenic overactive bladder (OAB) and (IC
  • kidney diseases in particular of acute and chronic renal insufficiency. as of acute and chronic renal failure.
  • renal insufficiency encompasses both acute and chronic manifestations of renal insufficiency, as well as underlying or related kidney diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis, acute glomerulonephritis, glomerulosclerosis, tubulo-interstitial diseases, nephropathic diseases such as primary and congenital kidney disease, nephritis, immunological kidney diseases such as kidney transplant rejection, immune complex-induced kidney disease, nephropathy induced by toxic substances, contrast agent-induced nephropathy, diabetic and nondiabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertens
  • the present invention also encompasses the use of the combinations of the invention for the treatment and / or prophylaxis of sequelae of renal insufficiency, such as pulmonary edema, cardiac insufficiency, uremia, anemia, electrolyte disorders (eg, hyperkalemia, hyponatremia), and disorders in bone and carbohydrate metabolism.
  • sequelae of renal insufficiency such as pulmonary edema, cardiac insufficiency, uremia, anemia, electrolyte disorders (eg, hyperkalemia, hyponatremia), and disorders in bone and carbohydrate metabolism.
  • the combinations of the invention are also suitable for the treatment and / or prophylaxis of asthmatic diseases, lung diseases such.
  • PAH Pulmonary arterial hypertension
  • PH pulmonary hypertension
  • COPD chronic obstructive pulmonary disease
  • ARDS acute respiratory syndrome
  • A-Ll acute lung injury
  • AATD alpha-1-antitrypsin defic
  • the combinations according to the invention are also suitable for regulating cerebral perfusion and are, for example, effective agents for controlling vascular cerebral dementia and migraine. They are also suitable for the prophylaxis and control of the consequences of cerebral infarct events (apoplexia cerebri) such as stroke, cerebral ischaemias and craniocerebral trauma. Furthermore, they are also suitable for treating development of various forms of epilepsy. Likewise, the combinations according to the invention can be used to combat pain and tinnitus.
  • the combinations according to the invention have anti-inflammatory action and can therefore be used as anti-inflammatory agents for the treatment and / or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory diseases of the kidney, chronic intestinal inflammation (IBD, Crohn 's Disease, UC). , Pancreatitis, peritonitis, rheumatoid diseases, inflammatory skin diseases as well as inflammatory eye diseases.
  • SIRS sepsis
  • MODS multiple organ failure
  • IBD chronic intestinal inflammation
  • Crohn 's Disease UC
  • Pancreatitis peritonitis
  • rheumatoid diseases inflammatory skin diseases as well as inflammatory eye diseases.
  • combinations according to the invention can likewise be used for the treatment and / or prophylaxis of autoimmune diseases.
  • the combinations according to the invention for the treatment and / or prophylaxis of fibrotic diseases of the internal organs such as the lung, heart, kidney, skin, bone marrow and especially the liver, as well as dermatological fibroses and fibrotic diseases of the eye suitable.
  • fibrotic disorders includes in particular the following terms liver fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage as a result of diabetes, bone marrow fibrosis and similar fibrotic diseases, systemic sclerosis, scleroderma , digital ulcerations, morphea, keloids, hypertrophic scarring (also after surgical interventions), nevi, diabetic retinopathy, proliferative vitroretinopathy and connective tissue disorders (eg sarcoidosis).
  • the combinations according to the invention are suitable for combatting postoperative scar formation, e.g. as a result of glaucoma surgery.
  • the combinations according to the invention can be used alone or as needed in combination with other active ingredients.
  • Another object of the present invention are pharmaceutical compositions containing at least one of the combinations according to the invention and one or more further active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • Suitable combination active ingredients are as follows: the active substances lowering the blood pressure, by way of example and preferably from the group of angiotensin II receptor antagonists, ACE inhibitors, calcium antagonists, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists and diuretics; • organic nitrates and NO donors, such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
  • cGMP cyclic guanosine monophosphate
  • PDE phosphodiesterases
  • Antithrombotic agents by way of example and preferably from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances;
  • Lipid metabolism-modifying agents by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as, for example, and HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR alpha, PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors and lipoprotein (a) antagonists.
  • cholesterol synthesis inhibitors such as, for example, and HMG-CoA reductase or squalene synthesis inhibitors
  • ACAT inhibitors such as, for example, and HMG-CoA reductase or squalene synthesis inhibitors
  • CETP inhibitors such as, for example, and HMG-CoA reductase or squalene synthesis inhibitors
  • CETP inhibitors such as, for example, and H
  • Antithrombotic agents are preferably understood as meaning compounds from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances.
  • the combinations according to the invention are administered in combination with a platelet aggregation inhibitor, such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • a platelet aggregation inhibitor such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • the combinations according to the invention are administered in combination with a thrombin inhibitor, such as, by way of example and by preference, ximaglagatran, dabigatran, melagatran, bivalirudin or Clexane.
  • a thrombin inhibitor such as, by way of example and by preference, ximaglagatran, dabigatran, melagatran, bivalirudin or Clexane.
  • the combinations according to the invention are administered in combination with a GPIIb / IIIa antagonist, such as, by way of example and by way of preference, tirofiban or abciximab.
  • the combinations according to the invention are used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaroxaban, DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondaparinux, idraparinux, PMD-31 12, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.
  • a factor Xa inhibitor such as by way of example and preferably rivaroxaban, DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondaparinux, idraparinux, PMD-31 12, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV
  • the combinations according to the invention are administered in combination with heparin or a low molecular weight (LMW) heparin derivative.
  • LMW low molecular weight
  • the combinations according to the invention are administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarin.
  • antihypertensive agents are preferably compounds from the group of calcium antagonists, angiotensin II receptor antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid Receptor antagonists and diuretics understood.
  • the combinations according to the invention are administered in combination with a calcium antagonist, such as by way of example and preferably fedipin, amlodipine, verapamil or diltiazem.
  • a calcium antagonist such as by way of example and preferably fedipin, amlodipine, verapamil or diltiazem.
  • the combinations according to the invention are administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin.
  • the combinations according to the invention are used in combination with a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipropanol, nadolol, mepindolol, Caroteneol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.
  • a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol
  • the combinations according to the invention are administered in combination with an angiotensin all-antagonist, such as by way of example and preferably losartan, valsartan, candesartan, embusartan, olmesartan, olmesartan-medoxomil, eprosartan, azilsartan or telmisartan.
  • an angiotensin all-antagonist such as by way of example and preferably losartan, valsartan, candesartan, embusartan, olmesartan, olmesartan-medoxomil, eprosartan, azilsartan or telmisartan.
  • the combinations according to the invention are administered in combination with an ACE inhibitor, such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an ACE inhibitor such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan or sitaxsentan.
  • the combinations according to the invention are administered in combination with a renin inhibitor, such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • a renin inhibitor such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • the combinations according to the invention are administered in combination with a mineralocorticoid receptor antagonist, such as by way of example and preferably spironolactone or eplerenone.
  • a mineralocorticoid receptor antagonist such as by way of example and preferably spironolactone or eplerenone.
  • the combinations of the invention are used in combination with a loop diuretic such as furosemide, torasemide, bumetanide and piretanide with potassium sparing diuretics such as amiloride and triamterene with aldosterone antagonists such as spironolactone, potassium canrenoate and eplerenone and thiazide diuretics such as Hydrochlorothiazide, chlorthalidone, xipamide, and indapamide.
  • lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, the ACAT inhibitors, MTP inhibitors, PPAR alpha- , PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and lipoprotein (a) antagonists understood.
  • CETP inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • ACAT inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • MTP inhibitors MTP inhibitors
  • PPAR alpha- , PPAR gamma and / or PPAR delta agonists cholesterol absorption inhibitors
  • polymeric bile acid adsorbers bile acid reab
  • the combinations according to the invention are administered in combination with a CETP inhibitor, such as, for example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
  • a CETP inhibitor such as, for example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
  • CETP vaccine CETi-1
  • the combinations according to the invention are administered in combination with a thyroid receptor agonist, such as by way of example and preferably D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).
  • the combinations according to the invention are administered in combination with an HMG-CoA reductase inhibitor from the class of statins, such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
  • statins such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
  • the combinations according to the invention are administered in combination with a squalene synthesis inhibitor, such as by way of example and preferably BMS-188494 or TAK-475.
  • the combinations according to the invention are administered in combination with an ACAT inhibitor, such as by way of example and preferably avasimbe, melinamide, pactimibe, eflucimibe or SMP-797.
  • an ACAT inhibitor such as by way of example and preferably avasimbe, melinamide, pactimibe, eflucimibe or SMP-797.
  • the combinations according to the invention are administered in combination with an MTP inhibitor, such as by way of example and preferably implitapide, BMS-201038, R-103757 or JTT-130.
  • the combinations according to the invention are administered in combination with a PPAR-gamma agonist, such as by way of example and preferably pioglitazone or rosiglitazone.
  • the combinations according to the invention are administered in combination with a PPAR delta agonist, such as by way of example and preferably GW 501516 or BAY 68-5042.
  • the combinations according to the invention are administered in combination with a cholesterol absorption inhibitor, such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • a cholesterol absorption inhibitor such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • the combinations according to the invention are administered in combination with a lipase inhibitor, such as, for example and preferably, orlistat.
  • a lipase inhibitor such as, for example and preferably, orlistat.
  • the combinations according to the invention are administered in combination with a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • the combinations according to the invention are administered in combination with a lipoprotein (a) antagonist, such as by way of example and preferably gemcabene calcium (CI-1027) or nicotinic acid.
  • a lipoprotein (a) antagonist such as by way of example and preferably gemcabene calcium (CI-1027) or nicotinic acid.
  • the combinations according to the invention are administered in combination with a myosin activator, such as, for example, Omecamtiv mercabil.
  • the combinations according to the invention are administered in combination with an HCN channel inhibitor, such as, for example, ivabradine.
  • an HCN channel inhibitor such as, for example, ivabradine.
  • the components can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic or as an implant or stent.
  • the combinations according to the invention can be administered in suitable administration forms.
  • the inventive combinations rapidly and / or modified donating application forms containing the compounds which are part of the combination in crystalline and / or amorphous and / or dissolved form, such as eg Tablets (uncoated or coated tablets, for example with enteric or delayed-release or insoluble coatings, which control the release of the compounds on which the combinations according to the invention are based), tablets or films rapidly breaking down in the oral cavity, films / lyophilisates, capsules ( hard or soft gelatin capsules, for example), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
  • eg Tablets uncoated or coated tablets, for example with enteric or delayed-release or insoluble coatings, which control the release of the compounds on which the combinations according to the invention are based
  • tablets or films rapidly breaking down in the oral cavity, films / lyophilisates, capsules ( hard or soft gelatin capsules, for example), dragees, granules, pellets,
  • Preferred forms of administration include tablet form (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compounds on which the combinations according to the invention are based), tablets or films rapidly disintegrating in the oral cavity.
  • Wafers, and particularly preferred forms of administration are tablet form (uncoated or coated tablets, for example, with enteric or delayed-dissolving or insoluble coatings which control the release of components underlying the combinations of the invention), tablets or films / wafers rapidly disintegrating in the oral cavity.
  • the parenteral administration can be done bypassing a resorption step (eg, intravenous, intraarterial, intracardiac, intraspinal, or intralumbar) or with involvement of resorption (eg, intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal).
  • a resorption step eg, intravenous, intraarterial, intracardiac, intraspinal, or intralumbar
  • involvement of resorption eg, intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal.
  • Renteral administration are suitable as forms of application, inter alia, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Inhalation medicaments including powder inhalers, nebulizers
  • nasal drops solutions or sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or eye preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (eg plasters)
  • milk pastes, foams, powdered powders, implants or stents.
  • oral or parenteral administration is preferred.
  • oral administration is more preferred.
  • the components can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • excipients for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecyl sulfate, polyoxysorbitanoleate
  • binders for example polyvinylpyrrolidone
  • synthetic and natural polymers for example albumin
  • Stabilizers eg, antioxidants such as ascorbic acid
  • dyes eg, inorganic pigments such as iron oxides
  • flavor and / or odoriferous the components can be administered together or sequentially or separately in a combined unit dosage form, in two separate unit dosage forms, or in three separate unit dosage forms.
  • the unit dosage form may also be a fixed combination
  • a therapeutically effective amount of each component of the combination of the invention may be administered simultaneously or sequentially in any order.
  • the components may be in a so-called sustained-release formulation, in which the release of the components according to the invention takes place at different times.
  • a sustained-release formulation in which the release of the components according to the invention takes place at different times.
  • the dosage of the selective partial adenosine A1 receptor agonist when dosed orally, is about 5-40 mg. In one embodiment of the invention, in oral administration, the dosage of the SGLT-2 inhibitor is about 10-100 mg od.
  • dosages described above may be formulated within the scope of the invention as a fixed-dose combination, wherein the preferred unitary forms may be tablets or capsules.
  • the dosage of the selective partial adenosine A1 receptor agonist is about 5-40 mg od, the dosage of the SGLT-2 inhibitor about 10 mg OD, also preferred is the dosage of the selective partial adenosine A1 receptor agonist about 5-40 mg od, the dosage of SGLT-2 inhibitor about 20 mg OD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des agonistes partiels sélectifs du résepteur A1 de l'adénosine en combinaison avec des inhibiteurs de SGLT-2 (transporteur de glucose dépendant du sodium: sodium dependent glucose transporter), et leur utilisation pour le traitement et/ou la prévention de maladie cardiovasculaire et rénales.
PCT/EP2018/054246 2017-02-22 2018-02-21 Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2 WO2018153900A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157405 2017-02-22
EP17157405.6 2017-02-22

Publications (1)

Publication Number Publication Date
WO2018153900A1 true WO2018153900A1 (fr) 2018-08-30

Family

ID=58158877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/054246 WO2018153900A1 (fr) 2017-02-22 2018-02-21 Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2

Country Status (1)

Country Link
WO (1) WO2018153900A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021004388A1 (fr) * 2019-07-05 2021-01-14 山东丹红制药有限公司 Forme cristalline d'inhibiteur de sglt et son application

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025210A2 (fr) 1999-10-01 2001-04-12 Bayer Aktiengesellschaft 2-thio-3,5-dicyano-4-aryl-6-aminopyridine substituee et son utilisation
WO2002070484A1 (fr) 2001-03-05 2002-09-12 Bayer Aktiengesellschaft 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation
WO2002070485A1 (fr) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft 2-thio-3,5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation comme ligands selectifs de recepteurs d'adenosine
WO2002070520A1 (fr) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft 2, 6-diamino-3, 5-dicyano-4-aryl-pyridines substituees et leur utilisation comme ligands selecteurs du recepteur d'adenosine
WO2003053441A1 (fr) 2001-12-11 2003-07-03 Bayer Healthcare Ag 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
WO2006027142A1 (fr) 2004-09-03 2006-03-16 Bayer Healthcare Ag Phenylaminothiazoles substitues, et leur utilisation
WO2007073855A1 (fr) 2005-12-23 2007-07-05 Bayer Healthcare Ag Utilisation d’agonistes des recepteurs a1 de l’adenosine en vue de proteger les cellules renales contre les effets toxiques induits par des aminoglycosides au cours du traitement de maladies infectieuses
WO2008028590A1 (fr) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de bipyridine substitués et leur utilisation en tant que ligands du récepteur d'adénosine
WO2008064788A1 (fr) 2006-12-01 2008-06-05 Bayer Schering Pharma Aktiengesellschaft 3,5-dicyano-2-thiopyridines substituées de manière cyclique et leur utilisation
WO2008064789A1 (fr) 2006-12-01 2008-06-05 Bayer Schering Pharma Aktiengesellschaft 4-amino-3,5-dicyano-2-thiopyridine substituée et son utilisation
WO2009015811A1 (fr) 2007-08-01 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Prodrogues dipeptoïdes et leur utilisation
WO2009015776A1 (fr) 2007-07-27 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Aryloxazoles substitués et leur utilisation
WO2009015812A2 (fr) 2007-08-01 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Prodrogues et leur utilisation
WO2009080197A1 (fr) 2007-12-20 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Pyrrolo[2,3-b]- et pyrazolo[3,4-b]-pyridines substituées comme ligands de récepteur de l'adénosine
WO2009100827A1 (fr) 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft 4-phényl-3,5-dicyanopyridines substituées par un groupe cycloalkoxy, et leur utilisation
WO2009112155A1 (fr) 2008-03-11 2009-09-17 Bayer Schering Pharma Ag Dicyanopyridines substituées par hétéroaryle et leur utilisation dans le traitement des maladies cardiovasculaires
WO2009143992A1 (fr) 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridines substituées par du 2-alcoxy et leur utilisation
WO2010072314A1 (fr) 2008-12-16 2010-07-01 Bayer Schering Pharma Ag Promédicaments dipeptoïdes et leur utilisation
WO2010072315A1 (fr) 2008-12-16 2010-07-01 Bayer Schering Pharma Ag Promédicaments d'esters d'acides aminés et leur utilisation
WO2010086101A1 (fr) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridine à substitution alkylamino et ses promédicaments d'ester d'acide aminé

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025210A2 (fr) 1999-10-01 2001-04-12 Bayer Aktiengesellschaft 2-thio-3,5-dicyano-4-aryl-6-aminopyridine substituee et son utilisation
WO2002070484A1 (fr) 2001-03-05 2002-09-12 Bayer Aktiengesellschaft 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation
WO2002070485A1 (fr) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft 2-thio-3,5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation comme ligands selectifs de recepteurs d'adenosine
WO2002070520A1 (fr) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft 2, 6-diamino-3, 5-dicyano-4-aryl-pyridines substituees et leur utilisation comme ligands selecteurs du recepteur d'adenosine
WO2003053441A1 (fr) 2001-12-11 2003-07-03 Bayer Healthcare Ag 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
WO2006027142A1 (fr) 2004-09-03 2006-03-16 Bayer Healthcare Ag Phenylaminothiazoles substitues, et leur utilisation
WO2007073855A1 (fr) 2005-12-23 2007-07-05 Bayer Healthcare Ag Utilisation d’agonistes des recepteurs a1 de l’adenosine en vue de proteger les cellules renales contre les effets toxiques induits par des aminoglycosides au cours du traitement de maladies infectieuses
WO2008028590A1 (fr) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de bipyridine substitués et leur utilisation en tant que ligands du récepteur d'adénosine
WO2008064788A1 (fr) 2006-12-01 2008-06-05 Bayer Schering Pharma Aktiengesellschaft 3,5-dicyano-2-thiopyridines substituées de manière cyclique et leur utilisation
WO2008064789A1 (fr) 2006-12-01 2008-06-05 Bayer Schering Pharma Aktiengesellschaft 4-amino-3,5-dicyano-2-thiopyridine substituée et son utilisation
WO2009015776A1 (fr) 2007-07-27 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Aryloxazoles substitués et leur utilisation
WO2009015811A1 (fr) 2007-08-01 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Prodrogues dipeptoïdes et leur utilisation
WO2009015812A2 (fr) 2007-08-01 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Prodrogues et leur utilisation
WO2009080197A1 (fr) 2007-12-20 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Pyrrolo[2,3-b]- et pyrazolo[3,4-b]-pyridines substituées comme ligands de récepteur de l'adénosine
WO2009100827A1 (fr) 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft 4-phényl-3,5-dicyanopyridines substituées par un groupe cycloalkoxy, et leur utilisation
WO2009112155A1 (fr) 2008-03-11 2009-09-17 Bayer Schering Pharma Ag Dicyanopyridines substituées par hétéroaryle et leur utilisation dans le traitement des maladies cardiovasculaires
WO2009143992A1 (fr) 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridines substituées par du 2-alcoxy et leur utilisation
WO2010072314A1 (fr) 2008-12-16 2010-07-01 Bayer Schering Pharma Ag Promédicaments dipeptoïdes et leur utilisation
WO2010072315A1 (fr) 2008-12-16 2010-07-01 Bayer Schering Pharma Ag Promédicaments d'esters d'acides aminés et leur utilisation
WO2010086101A1 (fr) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Dicyanopyridine à substitution alkylamino et ses promédicaments d'ester d'acide aminé
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities", 1985, ELSEVIER SCIENCE PUBLISHERS B.V.
BIOORG. MED. CHEM., vol. 6, 1998, pages 619 - 641
CURR. DRUG METAB., vol. 4, 2003, pages 461 - 485
CURR. EYE RES., vol. 26, 2004, pages 151 - 163
CURR. TOPICS MED. CHEM., vol. 3, 2003, pages 369 - 385
EXP. OPIN. INVEST. DRUGS, vol. 17, 2008, pages 1901 - 1910
J. BIOL. CHEM., vol. 267, 1992, pages 10764 - 10770
J. MED. CHEM., vol. 38, 1995, pages 4000 - 4006
J. MED. CHEM., vol. 47, 2004, pages 2393 - 2404
NAUNYN SCHMIEDEBERGS ARCH. PHARMACOL., vol. 357, 1998, pages 1 - 9
NEW ENGL. J. MED., vol. 373, 2015, pages 2117 - 28
SILVIO E INZUCCHI ET AL: "SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials", DIABETES & VASCULAR DISEASE RESEARCH, 1 March 2015 (2015-03-01), London, England, pages 90 - 100, XP055474025, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459/pdf/10.1177_1479164114559852.pdf> DOI: 10.1177/1479164114559852 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021004388A1 (fr) * 2019-07-05 2021-01-14 山东丹红制药有限公司 Forme cristalline d'inhibiteur de sglt et son application

Similar Documents

Publication Publication Date Title
TWI694072B (zh) 經羥烷基取代之苯基三唑衍生物及其用途
JP5826773B2 (ja) ビスアリール−結合アリールトリアゾロン及びその用途
JP5896991B2 (ja) 置換された５−フルオロ−１ｈ−ピラゾロピリジン及びそれらの使用
EP2729476B1 (fr) Pyrazolopyridines hétéroaryl substituées et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
EP2699578B1 (fr) Pyrazolopyridines substituées par un fluoro-alkyle et leur utilisation
EP3004094B1 (fr) Imidazo[1,2-a]pyridines à substitution 3-aryle et leur utilisation
EP2822951B1 (fr) Azabicyles substitués et leur utilisation
JP6911052B2 (ja) オキソアルキル置換フェニルトリアゾール誘導体およびその使用
EP3325013B1 (fr) Stimulateurs / activateurs de guanylate cyclase soluble en combinaison avec un inhibiteur de l&#39;endopeptidase neutrale (nep) et/ou un antagonist d&#39;angiotensin ii et son utilisation
EP2914595A1 (fr) Imidazo[1,2-a]pyridincarboxamides carboxy-substitués et leur utilistaion comme stimulants de la guanylate cyclase soluble
EP3525779B1 (fr) Combinaison contenant le stimulateur sgc vericugat et l&#39;antagoniste des récepteurs minéralcorticoïdes finerenone
DE102006054757A1 (de) Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2018069148A1 (fr) Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
EP2408754A1 (fr) Dérivés de triazole en tant qu&#39;inhibiteurs des récepteurs de vasopressine pour le traitement de l&#39;insuffisance cardiaque
WO2015018808A1 (fr) Imidazo[1,2-a]pyrazincarboxamides substitués et leur utilisation
EP4259616B1 (fr) Acides carboxyliques de pyrazolo pipéridine substitués
WO2015036563A1 (fr) Trifluorométhylpyrimidones disubstituées et leur utilisation comme antagonistes du ccr2
EP4259618B1 (fr) Acides pyrazolylpipéridine carboxyliques substitués
US11173151B2 (en) Substituted triazole derivatives and uses thereof
EP2556831A1 (fr) 6-Carbonitriles de 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine en tant que ligand pour le récepteur Adenosin pour le traitement des maladies cardiovasculaires
WO2018153900A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l&#39;adénosine en combinaison avec des inhibiteurs de sglt-2
WO2009156089A1 (fr) Dyaryle-urées pour le traitement de l&#39;insuffisance cardiaque
WO2018153898A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l&#39;adénosine en combinaison avec des antagonistes du récepteur des minéralocorticoïdes
WO2018153899A1 (fr) Agonistes partiels sélectifs du récepteur a1 de l&#39;adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
JP2011525503A (ja) 心不全を処置するためのジアリールウレア

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18705414

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18705414

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载